FRA:NOV - Deutsche Boerse Ag - DK0062498333 - Common Stock - Currency: EUR
Overall NOV gets a fundamental rating of 7 out of 10. We evaluated NOV against 50 industry peers in the Pharmaceuticals industry. NOV gets an excellent profitability rating and is at the same time showing great financial health properties. NOV is growing strongly while it is still valued neutral. This is a good combination! This makes NOV very considerable for growth and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.39% | ||
ROE | 75.51% | ||
ROIC | 44.39% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 46.51% | ||
PM (TTM) | 34.51% | ||
GM | 84.33% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.7 | ||
Debt/FCF | 1.6 | ||
Altman-Z | 5.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.74 | ||
Quick Ratio | 0.56 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 19.31 | ||
Fwd PE | 13.67 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 27.13 | ||
EV/EBITDA | 12.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.6% |
FRA:NOV (7/4/2025, 7:00:00 PM)
60.84
+2.09 (+3.56%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.6% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 19.31 | ||
Fwd PE | 13.67 | ||
P/S | 6.65 | ||
P/FCF | 27.13 | ||
P/OCF | 15.37 | ||
P/B | 14.56 | ||
P/tB | 69.17 | ||
EV/EBITDA | 12.99 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.39% | ||
ROE | 75.51% | ||
ROCE | 55.72% | ||
ROIC | 44.39% | ||
ROICexc | 53.11% | ||
ROICexgc | 110% | ||
OM | 46.51% | ||
PM (TTM) | 34.51% | ||
GM | 84.33% | ||
FCFM | 24.53% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.7 | ||
Debt/FCF | 1.6 | ||
Debt/EBITDA | 0.6 | ||
Cap/Depr | 284.1% | ||
Cap/Sales | 18.77% | ||
Interest Coverage | 108.03 | ||
Cash Conversion | 81.52% | ||
Profit Quality | 71.08% | ||
Current Ratio | 0.74 | ||
Quick Ratio | 0.56 | ||
Altman-Z | 5.27 |